![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PHARMACOPEIA, ORGANON EXTEND DEVELOPMENT COLLABORATION
PHARMACOPEIA, ORGANON EXTEND DEVELOPMENT COLLABORATION
August 30, 2005
Pharmacopeia announced that it has extended its collaboration with N.V. Organon. The partnership has delivered multiple lead series that are currently being advanced toward or through preclinical toxicological studies in anticipation of initiating clinical trials. As a consequence of the success to date, the collaboration, initiated in 2002, has been extended to 2007. Organon elected to continue the collaboration by accepting the latest preclinical lead candidate generated by Pharmacopeia's integrated and proprietary drug discovery and development platform.
Under the terms of the initial agreement, as amended, acceptance of this latest lead candidate prior to the end of 2005, along with clear progress on further lead series, resulted in the continuation of the collaboration. The collaboration goals remain unchanged and involve the companies working together to produce advanced preclinical lead compounds meeting stringent criteria for potency, physicochemical properties, in vivo pharmacokinetics and efficacy in relevant animal models.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct